2025年欧洲专家实验室SARS-CoV-2与RSV分子检测及变异分型外部质量评估
AURORAE联盟第四次SARS-CoV-2湿实验室外部质量评估(EQA)暨第二次组织,首次纳入RSV A/B组。37家来自32个欧洲国家的实验室参与,23家(62%)正确检出全部10份面板样本,20家(54%)正确判定RSV组别;低病毒载量RSV检测与低浓度样本谱系鉴定具有挑战性。
要点
- SARS-CoV-2分子检测在欧洲专家实验室已达持续高水平
- 低病毒载量RSV样本的分子检测具有挑战性
- 低浓度样本的谱系鉴定困难,需持续EQA监测
核心结论
- 欧洲专家实验室SARS-CoV-2分子检测能力随时间改善并达持续高水平。
- 低病毒载量RSV分子检测及低浓度样本谱系鉴定仍具挑战性。
- 通过EQA常规监测诊断与监测检测对维持公共卫生实验室快速响应至关重要。
研究设计与样本
- AURORAE联盟组织的第四次SARS-CoV-2湿实验室EQA,首次纳入RSV A/B组检测评估。
- 制备并验证含多种SARS-CoV-2变异株、RSV谱系、普通感冒冠状病毒及阴性对照的10份样本面板。
- 由ECDC邀请,37家来自32个欧洲国家的实验室参与并通过电子表格提交结果与检测细节。
主要发现
- 23家实验室(23/37;62%)通过分子检测正确识别全部面板样本。
- 23家(23/37;62%)使用商业试剂,14家(14/37;38%)使用自制试剂,8家(8/37;22%)两者兼用。
- 20家实验室(20/37;54%)正确判定RSV组别。
- 6家实验室开展可选RSV测序,仅2家获得序列。
临床怎么用
- 欧洲专家实验室应将EQA常规参与纳入分子诊断与变异监测的质量保障体系。
- 对低病毒载量RSV样本检测及低浓度样本谱系鉴定需重点关注并持续改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We herein report on the fourth SARS-CoV-2 wet-lab external quality assessment (EQA) and the second organized by the AURORAE consortium to assess the diagnostic capabilities of European expert public health laboratories. Diagnostic capabilities were investigated regarding SARS-CoV-2 and, for the first time, respiratory syncytial virus (RSV) groups A and B. A 10-sample panel containing various SARS-CoV-2 variants, RSV lineages, a common cold coronavirus, and a negative control was produced and validated. Participants were invited by the European Centre for Disease Prevention and Control (ECDC) and asked to submit results and assay details via electronic forms. Thirty-seven laboratories from 32 European countries participated. All panel samples were identified correctly via molecular detection by 23 participating laboratories (23/37; 62%). Commercial assays were used most often (23/37; 62%), in comparison to in-house assays (14/37; 38%), or a combination of both (8/37; 22%). RSV groups were correctly determined by 20 laboratories (20/37; 54%). The optional task of SARS-CoV-2 variant typing was performed by 20 laboratories using next-generation sequencing. Thirteen laboratories successfully generated SARS-CoV-2 sequences. Six laboratories performed optional RSV sequencing, with only two obtaining sequences. The current and previous EQAs show that molecular detection of SARS-CoV-2 within Europe has improved over time and is now at a consistently high level. Molecular detection of RSV samples with low viral load was challenging, as was lineage identification for low-concentration specimens. Routine monitoring of diagnostic and surveillance assays via EQAs remains key to maintaining rapid and long-lasting public health laboratory response systems.IMPORTANCEExternal quality assessments (EQAs) are essential for ensuring reliable and consistent diagnostic testing. They provide an objective way to evaluate laboratory performance, identify weaknesses, and drive improvements, as well as ensuring compliance with accreditation standards. Furthermore, participating in EQAs strengthens the contributions to public health disease surveillance and threat detection on national and transborder scales. During the SARS-CoV-2 pandemic, EQAs were vital for maintaining accuracy in the setting of increasing testing demands and emerging variants. Broadening of diagnostic testing to a wider panel of viruses, including respiratory syncytial virus (RSV), requires continuous performance monitoring to ensure accuracy and reliability. Ongoing development of vaccines and therapeutics, which may drive the emergence of new mutations, further underscores the need for regular evaluation of test effectiveness. By standardizing methods and reducing errors, EQAs ensure trustworthy and comparable results across laboratories. Regular participation in EQAs strengthens molecular diagnostics and variant surveillance.
引用
- Heimsch KC, Stanoeva KR, Visser I, et al. SARS-CoV-2 and RSV external quality assessment on molecular detection and variant typing in European expert laboratories in 2025. J Clin Microbiol. 2026. PMID: 42752180. doi:10.1128/jcm.00258-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。